Form 4: PTC Therapeutics EVP Lee Scott Golden Reports Sale of Common Stock for Tax Obligations
SEC Form 4 Filing
Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold 526 shares of common stock on April 2, 2024, to cover tax obligations related to vesting RSUs.
Summary
- On April 2, 2024, Lee Scott Golden, the EVP & Chief Medical Officer of PTC Therapeutics, sold 526 shares of the company's common stock.
- The sale was executed at a price of $28.37 per share.
- The transaction was conducted to satisfy tax withholding obligations associated with the vesting of 2,100 Restricted Stock Units (RSUs) from a grant made on April 24, 2023.
- Following the transaction, Golden directly owns 59,988 shares of PTC Therapeutics.
- The sale was automatically executed pursuant to an irrevocable sell-to-cover election.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't necessarily reflect a positive or negative outlook on the company's performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This particular filing reflects a common practice of executives selling shares to cover tax obligations related to the vesting of stock awards.
Key Dates
| Date | Description |
|---|---|
| 04/24/2023 | Date of RSU grant (8,400 RSUs), which triggered the tax obligation. |
| 04/02/2024 | Date of the stock sale transaction. |
| 04/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.